Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.

Also called NCT02151812

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 123 participants (enrolled count) (from the registry)
Sponsor
Hemoteq AG (from the registry)
Registry
  • NCT NCT02151812
Other papers using this trial's data
  • A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2020-07-17 DOI, PubMed 31746743

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France, Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02151812. Randomized; single masking; primary purpose treatment. Start 2014-08-13 (actual); primary completion 2017-04-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)
Acronym
AGENT-ISR
Condition
Coronary Restenosis
Condition
Coronary Atherosclerosis
Condition
Coronary Arteriosclerosis
Intervention (Device)
Agent Paclitaxel-coated balloon
Intervention (Device)
SeQuent® Please Paclitaxel-coated Balloon
Lead sponsor
Hemoteq AG (class: industry)

Record details

Record id
cardio:ct-nct02151812
Content hash
c9d38bd095013dba5124cf849340995d2f8d4a1a51ffd130c3f11cda20b88c40